Pharmaceutical Drugs Coverage

Cold Chain Temperature Monitoring Market Definition And Segments

Cold chain temperature monitoring refers to the process of continuously monitoring and tracking the temperature of perishable goods, pharmaceuticals, vaccines, and other temperature-sensitive products as they are transported or stored within a controlled environment. It utilizes various technologies, including sensors and data loggers, to consistently oversee the temperature conditions of perishable items to guarantee that these products are stored and transported within ideal temperature parameters, thereby preserving their quality, safety, and overall integrity. The main types of hardware used in cold chain temperature monitoring include conventional temperature loggers, real-time monitoring devices, resistance temperature detectors, temperature indicators, and others. Conventional temperature loggers refer to standard temperature monitoring devices used in cold chain logistics and monitoring to track and record temperature data at set intervals, ensuring the safe transportation and storage of perishable items like food and pharmaceuticals. The software types include on-premise and cloud-based for end users such as fish, meat, and seafood, processed food, pharmaceuticals, bakeries and confectionaries, fruits and vegetables, dairy products, and other end users. The cold chain temperature monitoring market covered in this report is segmented – 1) By Hardware: Conventional Temperature Loggers, Real Time Monitoring Devices, Resistance Temperature Detectors, Temperature Indicators, Other Hardware 2) By Software: On Premise, Cloud Based 3) By End User: Fish, Meat And Seafood, Processed Food, Pharmaceuticals, Bakery And Confectionaries, Fruits And Vegetables, Dairy Products, Other End Users The cold chain temperature monitoring market size has grown rapidly in recent years. It will grow from $7.52 billion in 2023 to $8.79 billion in 2024 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to increased global trade, rising demand for pharmaceutical products, importance of maintaining product quality, growing availability of cold chain logistics, focus on predictive maintenance. The cold chain temperature monitoring market size is expected to see rapid growth in the next few years. It will grow to $16.64 billion in 2028 at a compound annual growth rate (CAGR) of 17.3%. The growth in the forecast period can be attributed to integration of emerging technologies by key players, expansion and enhancement of product portfolios, adoption of innovative temperature monitoring solutions, increasing demand for cold chain tracking in developing countries, focus on automation and cold storage technologies. Major trends in the forecast period include increased use of sensors and data loggers, expansion of software solutions for cold chain monitoring, emphasis on security and safety in monitoring systems, Preference for on premise software solutions, focus on improving operational effectiveness.

E-Commerce Expansion Fuels Demand For Cold Chain Temperature Monitoring Solutions

The expansion of e-commerce is expected to propel the growth of the cold chain temperature monitoring market going forward. E-commerce refers to the buying and selling goods and services over an electronic network, primarily the internet. E-commerce expands due to its convenience, technological advancements, and accelerated adoption during the COVID-19 pandemic, enabling businesses to reach a global market while transforming supply chain logistics. Cold chain temperature monitoring systems provide real-time visibility and control over temperature-sensitive products, enabling e-commerce companies to maintain product quality, meet customer expectations, and demonstrate regulatory compliance. For instance, in November 2023, according to the United States Census Bureau, a US-based government agency, total e-commerce sales in the USA for 2023 were $1,118.7 billion, an increase of 7.6% from 2022. Therefore, the expansion of e-commerce is driving the growth of the cold chain temperature monitoring market. Major companies operating in the cold chain temperature monitoring market are Zebra Technologies Corporation, Cryoport Inc., Cold Chain Technologies, Controlant, Sensitech Inc., OMEGA Engineering inc., Luna, Elitech, MOBIQU, Thermo Electric Company Inc., DeltaTrak Inc., Berlinger & Co. AG, Insignia Technologies, Softbox, CargoSense, PakSense, Elpro-Buchs AG, CubeWorks, Infratab Inc., Kedeon, CWD Limited, ORBCOMM, Roambee Corporation, iMatrix Cloud, AeroSafe Global

Technology Solutions Driving Efficiency In Cold Chain Temperature Monitoring

Major companies operating in the cold chain temperature monitoring market are developing innovative temperature trackers, such as CubiSens XT1, to enhance real-time monitoring and ensure the integrity of temperature-sensitive products throughout the supply chain. CubiSens XT1 is a tracker that utilizes various sensor technologies to measure and record temperature conditions at different product transportation and storage stages. For instance, in September 2022, CubeWorks, a US-based technology company, launched CubiSens XT1. CubiSens XT1 aims to provide a comprehensive solution for monitoring and optimizing agricultural processes. It integrates various sensors and technologies to gather data on environmental conditions, crop health, soil moisture, and other relevant factors. The ultimate goal is to help farmers make informed decisions, increase crop yields, optimize resource usage, and improve overall efficiency and sustainability in agriculture.

Azenta Enhances Cold Chain Capabilities With Acquisition Of B Medical Systems SA

In October 2022, Azenta Inc., a US-based biotech company, acquired B Medical Systems SA for an undisclosed amount. This strategic acquisition strengthens Azenta's cold chain capabilities by integrating differentiated solutions for the dependable and traceable transport of temperature-sensitive specimens. SA is a Luxembourg-based medical refrigeration manufacturer offering cold chain temperature monitoring solutions. North America was the largest region in the cold chain temperature monitoring market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cold chain temperature monitoring market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cold chain temperature monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The cold chain temperature monitoring market consists of revenues earned by entities by providing services such as consulting and advisory services, temperature mapping and validation, data analytics and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The cold chain temperature monitoring market also includes sales of temperature labels and indicators, wireless temperature sensors, temperature monitoring systems, temperature probes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cold chain temperature monitoring research report is one of a series of new reports from The Business Research Company that provides cold chain temperature monitoring market statistics, including the cold chain temperature monitoring industry's global market size, regional shares, competitors with a cold chain temperature monitoring market share, detailed cold chain temperature monitoring market segments, market trends and opportunities, and any further data you may need to thrive in the cold chain temperature monitoring industry. This cold chain temperature monitoring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Lentiviral Vector Market Definition And Segments

A lentiviral vector refers to a type of viral vector derived from lentiviruses, a subgroup of retroviruses known for their ability to integrate genetic material into the DNA of the host cell's genome. These vectors are commonly used in molecular biology and gene therapy applications to deliver genetic material into target cells for various purposes, including gene expression, gene silencing, or genetic modification. The main types of products in the lentiviral vector are kits, reagents and consumables. Lentiviral vector kits encompass a comprehensive set of tools and components required for the generation and manipulation of lentiviral vectors. It can be used for various indications, including cancer, genetic disorders, infectious diseases, veterinary diseases, and others, and it includes various users such as biotechnology companies, pharmaceutical companies, contract research organizations (CROs), and academic and research institutes. The lentiviral vector market covered in this report is segmented – 1) By Product Type: Kits, Reagents And Consumables 2) By Indication: Cancer, Genetic Disorder, Infectious Disease, Veterinary Disease, Other Indications 3) By End User: Biotechnology Companies, Pharmaceutical Companies, Contract Research Organization (CRO), Academic And Research Institutes The lentiviral vector market size has grown rapidly in recent years. It will grow from $12.50 billion in 2023 to $14.37 billion in 2024 at a compound annual growth rate (CAGR) of 15.0%. The growth in the historic period can be attributed to prevalence of genetic disorders, gene delivery demand, biotech and pharma expansion, clinical trial investment, regulatory approvals. The lentiviral vector market size is expected to see rapid growth in the next few years. It will grow to $25.50 billion in 2028 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to personalized medicine growth, gene editing innovations, rare disease therapy demand, lentiviral vector adoption, genomic medicine funding, manufacturing scalability focus. Major trends in the forecast period include expansion of research and development, integration in CAR-T cell therapy, development of next-generation vectors, adoption in vaccine development, development of production technologies.

Lentiviral Vectors Market Driven By Rising Prevalence Of Chronic Diseases

The increasing prevalence of chronic diseases is expected to propel the lentiviral vectors market going forward. Chronic diseases refer to long-term medical conditions that typically progress slowly over time and often persist for years or even a lifetime. The prevalence of chronic diseases is increasing due to aging populations, unhealthy lifestyles, urbanization, and environmental factors. Lentiviral vectors offer versatile and efficient tools for developing vaccines and treatment strategies for chronic diseases, addressing unmet medical needs, and improving patient outcomes. For instance, in January 2023, according to the report published by the National Library of Medicine, the US-based medical library, It is expected that there will be around 142.66 million people with at least one chronic illness by 2050, a 99.5% rise from 71.522 million in 2020. Therefore, the increasing prevalence of chronic diseases is driving the growth of the lentiviral vectors market. Major companies operating in the lentiviral vector market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Agilent Technologies Inc., Amgen Inc., Merck KGaA, Lonza Group Ag, Cytiva, Charles River Laboratories, Bio-Rad Laboratories Inc., Promega Corporation, Takara Bio Inc., Sino Biological Inc., OriGene Technologies Inc., Applied Biological Materials Inc., Oxford Biomedica, Sirion-Biotech GmbH, Yposkesi

Technological Advancements In Lentiviral Vector Production For Immuno-Oncology Therapies

Major companies operating in the lentiviral vectors market are focusing on developing LV vector production platforms, such as LentiSure, to enhance the efficiency and robustness of producing lentivirus vectors for cell-based immuno-oncology therapies. LentiSure is the LV vector production platform producing lentiviral vectors used in cell-based immuno-oncology therapies. It is designed to enhance efficiency and robustness in generating vectors. For instance, in May 2023, Yposkesi sk pharmteco, a France-based manufacturer of viral vectors, launched LentiSure, an advanced platform designed to enhance the production of lentiviral (LV) vectors, aiming to improve the resilience and efficiency of lentivirus production. This platform addresses the growing demand for robust and economically scalable viral-vector manufacturing technologies in cell and gene therapies. It offers consistent product quality with average titers at cell culture harvest at 10e7 IG/mL bioreactor volume, ensuring higher productivity and success for cell therapy developers.

Charles River Laboratories Enhances Gene Therapy Capabilities With Vigene Biosciences Acquisition

In June 2021, Charles River Laboratories, a US-based pharmaceutical company, acquired Vigene Biosciences for $292.5 million. Through this acquisition, Charles River aimed to enhance its gene therapy capabilities, particularly in the high-growth cell and gene therapy CDMO sectors for viral vectors and plasmid DNA, to better meet the clients' evolving scientific needs. Vigene Biosciences is a US-based viral vector-based gene delivery service and product provider. North America was the largest region in the lentiviral vector market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lentiviral vector market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lentiviral vector market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The lentiviral vector market consists of sales of 3rd generation lentiviral vectors, Lenti-ORF clones, and lentiviral particles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The lentiviral vector market research report is one of a series of new reports from The Business Research Company that provides lentiviral vector market statistics, including lentiviral vector industry global market size, regional shares, competitors with a lentiviral vector market share, detailed lentiviral vector market segments, market trends and opportunities, and any further data you may need to thrive in the lentiviral vector industry. This lentiviral vector market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Pharma 4.0 Market Definition And Segments

Pharma 4.0, also known as Pharmaceutical 4.0, refers to the convergence of advanced digital technologies with the pharmaceutical industry, akin to the broader concept of Industry 4.0. It represents a transformative approach to pharmaceutical manufacturing and healthcare delivery, aiming to address rising costs, regulatory compliance, drug shortages, and the need for personalized treatments while unlocking new opportunities for innovation and improving patient care. The main components of pharma 4.0 are hardware, software, and services. Hardware refers to the physical components of a computer system or electronic device, including components such as the processor, memory, storage, and peripherals. Various technologies are used, such as cloud computing, artificial intelligence (AI), big data analytics, and the Internet of Things (IoT). These are used in many applications, including drug discovery and development, clinical trials, and manufacturing, and are used by a variety of end-users, mainly pharmaceutical companies, biotechnology companies, contract research organizations (CROs), and contract manufacturing organizations (CMOS). The pharma 4.0 market covered in this report is segmented – 1) By Component: Hardware, Software, Services 2) By Technology: Cloud Computing, Artificial Intelligence (Al), Big Data Analytics, Internet of Things (IoT) 3) By Application: Drug Discovery And Development, Clinical Trials, Manufacturing 4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organizations (CMOs) The pharma 4.0 market size has grown exponentially in recent years. It will grow from $14.92 billion in 2023 to $17.99 billion in 2024 at a compound annual growth rate (CAGR) of 20.5%. The growth in the historic period can be attributed to regulatory compliance and quality assurance, drug patent expirations and generic competition, increasing healthcare expenditure, demand for personalized medicine and biologics, globalization of pharmaceutical markets. The pharma 4.0 market size is expected to see exponential growth in the next few years. It will grow to $38.44 billion in 2028 at a compound annual growth rate (CAGR) of 20.9%. The growth in the forecast period can be attributed to shift towards value-based healthcare models, aging population and increased healthcare needs, demand for personalized medicine and precision therapeutics, regulatory reforms and changes in healthcare policies, growing emphasis on patient-centric care and outcomes. Major trends in the forecast period include personalized medicine and precision therapeutics, digital health technologies, value-based healthcare models, regulatory harmonization and accelerated approval processes, supply chain digitization and transparency.

Telemedicine And Remote Patient Monitoring Fuel Pharma 4.0 Market Growth

The expansion of telemedicine and remote patient monitoring is expected to propel the growth of the pharma 4.0 market going forward. Telemedicine refers to the practice of providing medical care and consultation remotely using telecommunications technology. Remote patient monitoring involves collecting, transmitting, and analyzing patient health data from a distance using technology-enabled devices and platforms. Telemedicine and remote patient monitoring are expanding due to technological advancements, increasing demand for convenient healthcare access, and the need to manage chronic conditions efficiently. Telemedicine and remote patient monitoring play significant roles in pharma 4.0, facilitating patient-centered care, enabling real-time data collection for personalized medicine, and enhancing pharmaceutical companies' ability to gather patient insights for drug development. For instance, in November 2022, according to Statistics Canada, a Canada-based government agency, one-fourth (24%) of healthcare workers in Canada delivered healthcare services remotely since March 2020, with phone consultations being the most common method, followed by video calls and other digital platforms. Furthermore, in October 2022, according to the Centers for Disease Control and Prevention, a US-based government agency, in the year 2021, telemedicine was utilized by 37.0% of individuals, which increased with age and was more prevalent among women (42.0%) than among men (31.7%). Therefore, the expansion of telemedicine and remote patient monitoring is driving the growth of the pharma 4.0 market. Major companies operating in the pharma 4.0 market are Alphabet Inc., Microsoft Corporation, Pfizer Inc., Johnson & Johnson, Amazon Web Services Inc., Roche Holding AG, International Business Machines Corporation, Merck & Co. Inc., Cisco Systems Inc., Bristol Myers Squibb Company, Oracle Corporation, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Honeywell International Inc., Fujitsu Limited, ABB Ltd., Siemens Healthineers, GE Healthcare, Lotte Corporation, SAS Institute Inc., Optum Inc., POLARISqb, Syntekabio, Optibrium

Adoption Of Cloud-Based Drug Discovery Platforms In Pharma 4.0 Market

Major companies operating in the pharma 4.0 market are developing cloud-based drug discovery platforms, such as StarDrop, to gain a competitive edge. StarDrop is a cloud-based drug discovery platform hosted on remote servers and accessed via the Internet, allowing researchers and pharmaceutical companies to carry out drug discovery activities such as compound screening, molecular modeling, and data analysis in a virtual environment. For instance, in October 2023, Optibrium Ltd., a UK-based biotechnology research company, launched a cloud-based version of its popular drug discovery platform, StarDrop. This platform aims to enhance accessibility and reduce the total cost of ownership for users. It retains all the functionality and interactivity of the desktop application. It allows users to access StarDrop from any internet-connected device, providing greater flexibility for researchers working remotely or across multiple locations. The cloud-based deployment is hosted on Amazon Web Services (AWS). It is supported by Optibrium's ISO 27001-accredited information security system, ensuring advanced data security, including encryption for secure data transfer and protection behind a firewall.

ProductLife Group Strengthens Market Position Through Acquisition Of Pharma IT ApS

In June 2022, ProductLife Group, a France-based specialized services company, acquired Pharma IT ApS for an undisclosed amount. The acquisition is expected to help ProductLife Group enhance its position in the market, especially in Northern Europe, and expand its service offerings within life sciences digitalization. Pharma IT ApS is a Denmark-based life sciences consulting company that provides consulting services for the medical device, biotech, and pharmaceutical industries. North America was the largest region in the pharma 4.0 market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the pharma 4.0 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharma 4.0 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The pharma 4.0 market consists of revenues earned by entities by providing services such as remote patient monitoring, virtual consultations, digital therapeutics, and medication adherence programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The Pharma 4.0 market also includes sales of digital twin platforms, smart manufacturing systems, patient engagement tools, and monitoring tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The pharma 4.0 market research report is one of a series of new reports from The Business Research Company that provides pharma 4.0 market statistics, including pharma 4.0 industry global market size, regional shares, competitors with a pharma 4.0 market share, detailed pharma 4.0 market segments, market trends and opportunities, and any further data you may need to thrive in the pharma 4.0 industry. This pharma 4.0 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Process Analytical Technology Market Definition And Segments

Process analytical technology refers to a framework for designing, analyzing, and controlling manufacturing processes by measuring critical process parameters (CPPs) and quality attributes in real time. It plays a crucial role in modern manufacturing by enabling real-time monitoring, analysis, and control of manufacturing processes to ensure consistent product quality, improve efficiency, and reduce production costs. The main products of process analytical technology are analyzers, sensors and probes, samplers, and software and services. Analyzers refer to instruments that are used to examine and measure various properties of substances or materials, providing valuable insights into their composition, quality, and characteristics. Various techniques were used, including spectroscopy, chromatography, particle size analysis, electrophoresis, and others. These are used in many applications, majorly small molecules, large molecules, manufacturing applications, and others, and are used in various end-user pharmaceutical companies, biotechnology companies, and others. The process analytical technology market covered in this report is segmented – 1) By Product: Analyzers, Sensors And Probes, Samplers, Software And Services 2) By Technique: Spectroscopy, Chromatography, Particle Size Analysis, Electrophoresis, Other Techniques 3) By Application: Small Molecules, Large Molecules, Manufacturing Applications, Other Applications 4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Other End-Users The process analytical technology market size has grown rapidly in recent years. It will grow from $2.68 billion in 2023 to $2.99 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to regulatory compliance, quality control requirements, cost reduction initiatives, globalization of supply chains, market competition. The process analytical technology market size is expected to see rapid growth in the next few years. It will grow to $4.68 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to sustainability initiatives, personalized medicine trends, industry 4.0 integration, emerging markets expansion, shift towards continuous manufacturing. Major trends in the forecast period include adoption of remote monitoring technologies, increased focus on data analytics and ai, expansion of digital twins, integration of blockchain for supply chain transparency, rise of personalized manufacturing.

Surging Demand For Personalized Medicine Fuels Growth In The Process Analytical Technology Market

The rising demand for personalized medicine is expected to propel the growth of the process analytical technology market going forward. Personalized medicine refers to an approach to medical treatment and healthcare that considers individual variability in genes, environment, and lifestyle for each person. The demand for personalized medicine is rising due to advancements in genomics, which allow tailored treatments based on individual genetic makeup and disease characteristics. Process analytical technology is utilized in personalized medicine to monitor and analyze critical parameters during the manufacturing of personalized treatments, such as gene therapies or customized medications, ensuring precise control over the production process to guarantee the quality and consistency of individualized therapies. For instance, according to the FDA's Center for Drug Evaluation and Research (CDER), a US-based crucial division of the U.S. Food and Drug Administration responsible for ensuring the availability of safe and effective drugs to enhance public health in the United States, in 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs). Out of the 35 therapeutic NMEs, approximately 34%, which amounts to 12 of them, are classified as personalized medicines. Therefore, the rising demand for personalized medicine is driving the growth of the process analytical technology market. Major companies operating in the process analytical technology market are Siemens AG, Thermo Fisher Scientific Inc., Danaher Corporation, ABB Ltd., GE Healthcare, Emerson Electric Co., Agilent Technologies Inc., Teledyne Technologies Incorporated, Sartorius AG, Mettler-Toledo, PerkinElmer Inc., Shimadzu Corporation, Waters Corporation, Bruker Corporation, HORIBA Ltd., Carl Zeiss AG, Nova Biomedical, TECAN Group Ltd., Repligen Corporation, Hamilton Company, Oxford Instruments plc, Malvern Panalytical, Hitachi High-Tech Analytical Science, JEOL Ltd., Yokogawa Electric Corporation

Single-Cell Analysis Devices Transforming The Process Analytical Technology Market

Major companies operating in the process analytical technology market are developing innovative products, such as new compact radiance instruments, to gain a competitive edge in the market. The new compact radiance instrument analyzes individual cells in a population, allowing for high-resolution characterization of cellular heterogeneity, responses, and behavior in real time during manufacturing. For instance, in October 2023, LumaCyte Inc., a US-based biotechnology company, launched a new compact radiance instrument specifically designed for advanced therapy biomanufacturing and quality control environments. The radiance instrument is a high-content, label-free microfluidic cell analyzer and sorter that can perform single-cell analysis and sorting. This innovative instrument is noteworthy for its small size, taking up only 16 inches of bench space while maintaining advanced technological capabilities. This technology is significant for applications in biomanufacturing and quality control environments, as it offers efficient and precise analytical capabilities.

Bruker Corporation Expands Biopharma PAT Portfolio With Tornado Spectral Systems Enhancing Quality Control Capabilities

In January 2024, Bruker Corporation, a US-based biotechnology research company, acquired Tornado Spectral Systems Inc. for an undisclosed amount. The acquisition aims to expand Bruker's biopharma process analytical technology (PAT) product portfolio by incorporating Tornado's innovative Raman instruments and enhancing capabilities in pharma and biotech quality control applications. Tornado Spectral Systems Inc. is a Canada-based analytical instrument company that provides process analytical technology. North America was the largest region in the process analytical technology market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the process analytical technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the process analytical technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The process analytical technology market consists of revenues earned by entities by providing services such as consulting services, custom development services, training and education, and customization and integration services. The market value includes the value of related goods sold by the service provider or included within the service offering. The process analytical technology market also includes sales of spectrometers, chromatography systems, process control software, and data management and integration platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The process analytical technology market research report is one of a series of new reports from The Business Research Company that provides process analytical technology market statistics, including process analytical technology industry global market size, regional shares, competitors with a process analytical technology market share, detailed process analytical technology market segments, market trends and opportunities, and any further data you may need to thrive in the process analytical technology industry. This process analytical technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Definition And Segments

Attention deficit hyperactivity disorder (ADHD) therapeutics refers to the range of treatments and interventions aimed at managing the symptoms and improving the functioning of individuals diagnosed with ADHD. ADHD is a neurodevelopmental disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity that significantly interfere with daily functioning and development. The primary objective of ADHD therapeutics is to enhance attention, impulse control, and overall functioning in daily activities, thereby improving the quality of life for individuals affected by ADHD. The main types of drugs in attention deficit hyperactivity disorder (ADHD) therapeutics are stimulants and non-stimulants. Stimulants are medications that increase certain chemicals in the brain, helping improve attention and focus. It includes various psychotherapies, such as behavior therapy, cognitive behavioral therapy, interpersonal psychotherapy, and family therapy, and is adapted for different age groups, including pediatric, adolescent, and adult, and distributed through hospital pharmacies, specialty clinics, retail pharmacies, and e-commerce. The attention deficit hyperactivity disorder (ADHD) therapeutics market covered in this report is segmented – 1) By Drug Type: Stimulants, Non-Stimulants 2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy 3) By Age Group: Pediatric And Adolescent, Adult 4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce The attention deficit hyperactivity disorder (ADHD) therapeutics market size has grown strongly in recent years. It will grow from $12.37 billion in 2023 to $13.21 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to diagnostic awareness and screening programs, rising incidence of ADHD, advancements in treatment modalities, healthcare infrastructure development, and health insurance coverage expansion. The attention deficit hyperactivity disorder (ADHD) therapeutics market size is expected to see strong growth in the next few years. It will grow to $16.42 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to genetic research and personalized medicine, increasing mental health awareness, global and national mental health initiatives, telehealth expansion, integration of behavioral therapies. Major trends in the forecast period include technological innovations in treatment, research and development initiatives, digital therapeutics integration, precision medicine approaches, innovations in drug delivery systems.

Rising Prevalence Of ADHD Spurs Growth In The Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutic Market

The increasing prevalence of attention-deficit hyperactivity disorder is expected to propel the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutics market going forward. The rising prevalence of attention-deficit hyperactivity disorder (ADHD) refers to the growing number of individuals diagnosed with this neurodevelopmental disorder over time. ADHS therapeutics address the multifaceted nature of the condition, aiming to improve symptom management, functional impairment, quality of life, and overall well-being for individuals affected by ADHD. For instance, in January 2023, according to reports published by the Guardian, a US-based news publishing company, an estimated 170,000 identified patients were prescribed for ADHD in 2022, a 20.4% increase from the 141,000 identified patients during the same period in 2021. Therefore, the increasing prevalence of ADHD is driving the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutic market. Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical's, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.

Leading Companies Innovate With Over-The-Counter (OTC) Digital Therapeutics For ADHD In The US Market

Major companies operating in the attention-deficit hyperactivity disorder (ADHD) therapeutics market are focusing on the development of digital advancements such as Endeavor over-the-counter (OTC) versions of digital therapeutics for ADHD to meet increased demand for digital solutions and the rise in demand for remote healthcare. Digital therapeutics are evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. These interventions are designed to be used independently or with traditional medical treatments. For instance, in June 2023, Akili, a US-based digital health company, launched an over-the-counter (OTC) version of its video game-based digital therapeutic for adults with attention-deficit hyperactivity disorder (ADHD). The OTC version, EndeavorOTC, is designed to improve attention, time management, and organizational skills. Additionally, this move follows the success of Akili's FDA-authorized prescription video game treatment, EndeavorRx, for children with ADHD. The OTC version provides adults with a non-drug treatment option for managing ADHD symptoms.

Optum Inc. Strengthens Behavioral Health Services With Acquisition Of Refresh Mental Health

In March 2022, Optum Inc., a US-based healthcare services provider company, acquired Refresh Mental Health for $700 million. This acquisition will enhance Optum's outpatient mental and behavioral health service provider position. It will expand its effective behavioral care to patients and drive deeper medical and behavioral health care integration. Refresh Mental Health is a US-based company offering various mental and behavioral health services, including ADHD psychiatry and therapy. North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The attention deficit hyperactivity disorder (ADHD) therapeutic market consists of revenues earned by entities by providing services such as medication management, behavioral therapy, social skills training, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The attention deficit hyperactivity disorder (ADHD) therapeutic market also includes sales of medication, behavioral modification tools, organization and planning tools, and assistive technologies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The attention deficit hyperactivity disorder (ADHD) therapeutics market research report is one of a series of new reports from The Business Research Company that provides attention deficit hyperactivity disorder (ADHD) therapeutics market statistics, including attention deficit hyperactivity disorder (ADHD) therapeutics industry global market size, regional shares, competitors with a attention deficit hyperactivity disorder (ADHD) therapeutics market share, detailed attention deficit hyperactivity disorder (ADHD) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the attention deficit hyperactivity disorder (ADHD) therapeutics industry. This attention deficit hyperactivity disorder (ADHD) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biologics CDMO Market Definition And Segments

A biologics contract development and manufacturing organization (CDMO) is a service provider that supports pharmaceutical companies in the development and production of biologic drugs, which include vaccines, blood and blood components, allergens, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins. The main cell types in biologics CDMO are mammalian and non-mammalian. Mammalian refers to cell lines derived from mammals, commonly used in the production of biologics and cell-based therapies due to their ability to produce complex proteins and maintain post-translational modifications. The various products types include biologics and biosimilars. The biologics CDMO market covered in this report is segmented – 1) By Cell Type: Mammalian, Non-Mammalian 2) By Product Type: Biologics, Biosimilars The biologics CDMO market size has grown rapidly in recent years. It will grow from $18.44 billion in 2023 to $21.30 billion in 2024 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to rise in biologics development, cost efficiency and flexibility, focus on core competencies, regulatory compliance and quality assurance, globalization of pharmaceutical supply chains. The biologics CDMO market size is expected to see rapid growth in the next few years. It will grow to $36.54 billion in 2028 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to increasing demand for biologic therapies, emergence of biosimilars and biobetters, investments in biomanufacturing infrastructure, shift towards outsourcing complex processes, focus on supply chain resilience and risk mitigation, regulatory harmonization, and expedited approvals. Major trends in the forecast period include expansion of capabilities to offer end-to-end solutions, adoption of single-use technologies, integration of continuous manufacturing processes, emergence of specialized CDMOs.

Rise In Demand For Cell And Genetic Therapy Fuels Biologics CDMO Market Growth

The surge in demand for cell and genetic therapy is expected to propel the growth of the biologic CDMO market going forward. Cell and gene therapy are innovative medical approaches that utilize living cells or genetic material to address underlying disease causes at the cellular or genetic level, providing potential treatments for conditions that are difficult to manage or incurable with traditional pharmaceuticals. The demand for cell and gene therapy is rising due to their potential to offer innovative treatments for diseases by addressing underlying genetic or cellular causes. Biologic CDMOs provide expertise in handling living cells, viral vectors, and genetic material, facilitating safe and efficient production of cell and gene therapies while assisting biopharmaceutical companies in navigating regulatory requirements and technical challenges, thereby facilitating translation from research to clinical application. For instance, in January 2023, according to The American Society of Gene & Cell Therapy (ASGCT), a US-based primary professional membership organization, the gene, cell, and RNA therapy pipeline saw 7% growth in 2022, reaching a total of 3,726 therapies in development. Of these, 55% are gene therapies, while 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Therefore, the surge in demand for cell and genetic therapy is driving the growth of the biologic CDMO market. Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

Advancements In Biologics CDMO

Major companies operating in the biologics CDMO market are developing technologically advanced solutions, such as new cell lines, to enhance biopharmaceutical development and manufacturing efficiency and capabilities. The technology produces therapeutic antibodies with enhanced potency, addressing immunotherapy research and development challenges. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company that specializes in the pharmaceutical and biotechnology sectors, launched GS Effex cell lines, designed to produce antibodies that are 100% free of fucose, a sugar molecule and demonstrate increased potency without compromising on other performance attributes. It helps overcome immunotherapy research and development challenges related to the need for antibody therapeutics to increase potency. It is a stable, scalable, and productive cell line that provides a solution for therapeutic development from discovery-stage research through commercial manufacturing.

Bora Pharmaceuticals Expands Global Footprint With Acquisition Of Eden Biologics Inc.

In May 2022, Bora Pharmaceuticals Co. Ltd., a Taiwan-based organization that specializes in manufacturing and selling pharmaceutical products, acquired the CDMO assets of Eden Biologics Inc. for $100 million. The aim of the acquisition is to expand its presence in the global CDMO market, particularly focusing on biologics, macromolecules, and cell and gene therapy markets. Eden Biologics Inc. is a Taiwan-based biotechnology company specializing in the contract development and manufacturing of innovative biologics for therapeutic applications. North America was the largest region in the biologics CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biologics CDMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The biologics CDMO market consist of revenues earned by entities by providing services such as process development, analytical development, cell line development, supply chain management, and fill-finish services. The biologics CDMO market also includes sales of monoclonal antibodies, recombinant proteins, antisense and molecular therapy, and vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biologics CDMO research report is one of a series of new reports from The Business Research Company that provides biologics CDMO market statistics, including the biologics CDMO industry's global market size, regional shares, competitors with an biologics CDMO market share, detailed biologics CDMO market segments, market trends and opportunities, and any further data you may need to thrive in the biologics CDMO industry. This biologics CDMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

High Throughput Screening (HTS) Market Definition And Segments

High-throughput screening (HTS) is a technique employed in drug discovery and various scientific domains to rapidly assess a large number of samples for biological activity. Its purpose is to identify active compounds, antibodies, or genes that modulate specific biological pathways, thereby expediting the drug discovery process. The main types of products and services in high-throughput screening (HTS) are consumables and reagents, instruments, software, and services. Consumables and reagents refer to the materials and chemicals used in the screening process, including sample containers, assay reagents, and other disposable items necessary for experimental procedures. The technology types are categorized into ultra-high-throughput screening, cell-based assays, lab-on-a-chip, and label-free technology, which are used in several applications such as target identification and validation, primary and secondary screening, toxicology assessment, and others. The end users include the pharmaceutical and biotechnology industries, academic and research institutes, contract research organizations, and others. The high throughput screening (HTS) market covered in this report is segmented – 1) By Products And Services: Consumables And Reagents, Instruments, Software And Services 2) By Technology: Ultra-High-Throughput Screening, Cell-Based Assays, Lab-on-a-chip, Label-Free Technology 3) By Application: Target Identification And Validation, Primary And Secondary Screening, Toxicology Assessment, Other Applications 4) By End User: Pharmaceuticals And Biotechnology Industry, Academics And Research Institute, Contract Research Organization, Other End Users The high throughput screening market size has grown rapidly in recent years. It will grow from $20.66 billion in 2023 to $22.98 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to increasing adoption of high-throughput screening, rising r&d spending, growing availability of funds for research, increasing healthcare spending, competitive market landscape. The high throughput screening market size is expected to see strong growth in the next few years. It will grow to $33.1 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing market size and growth rate, strategic developments by key players, rising demand for disease monitoring and drug discovery, rising prevalence of chronic diseases, growing focus towards implementation of ultra high throughput screening (UHTS) techniques. Major trends in the forecast period include technological advancements in high-throughput screening, growing focus towards implementation of ultra high throughput screening (UHTS) techniques.

Impact Of Chronic Disease Prevalence On High Throughput Screening (HTS) Market Growth

The rise in the prevalence of chronic diseases is expected to propel the growth of the high-throughput screening (HTS) market going forward. Chronic disease refers to a long-term health condition or disease that persists over an extended period, typically lasting for three months or more. HTS enables rapid screening of numerous chemical compounds to pinpoint potential drug candidates targeting specific pathways or mechanisms implicated in chronic diseases, essential for their effective long-term management For instance, in January 2023, according to a report published by the National Library of Medicine, a US-based medical library run by the federal government, the number of people aged 50 and older with one or more chronic diseases is expected to increase by 99.5%, totaling 142.66 million by 2050, compared to 71.522 million in 2020 in the United States of America. Therefore, the rise in the prevalence of chronic diseases will drive the growth of the high-throughput screening (HTS) market. Major companies operating in the high throughput screening (HTS) market are Thermo Fisher Scientific Inc., AstraZeneca Plc, Danaher Corporation, Merck Group, GE HealthCare Technologies Inc., Corning Inc., Agilent Technologies Inc., Lonza Group Ltd., Charles River Laboratories International Inc, Beckman Coulter Inc., PerkinElmer Inc., Bio-Rad Laboratories, Tecan Group Ltd., Sygnature Discovery Ltd., Luminex Corporation, Hamilton Company, Crown Bioscience Inc., HighRes Biosolutions, NanoTemper Technologies GmbH, BMG LABTECH GmbH, Axxam SpA, Reprocell Inc., BioTek Instruments Inc, Aurora Biomed Inc., Cyclica Inc., Biomat Srl, Diana Biotechnologies s.r.o

Innovative Multimode Plate Reader Revolutionizes High Throughput Screening Market

Major companies operating in the high-throughput screening market are developing innovative products, such as multimode plate readers, to better serve their customers with advanced features. A multimode plate reader (MPR) is an advanced lab tool used in high-throughput screening, analyzing biological and chemical samples in microplates by integrating multiple detection modes for diverse assays within a single platform. For instance, in February 2023, PerkinElmer Inc., a US-based MedTech company, launched the EnVision Nexus system. The EnVision Nexus system stands out as the fastest and most sensitive multimode plate reader available, explicitly designed for demanding high-throughput screening (HTS) applications to expedite drug discovery efforts. With its unique technology, including dual detectors and optimized reagents like proprietary HTRF and AlphaLISA, coupled with the latest reagent kits, the platform offers researchers unparalleled assay flexibility, accuracy, speed, and sensitivity. Equipped with walkaway convenience options such as a plate stacker for 20 or 50 plates or full automation and integration for continuous 24/7 workflow-driven operations, the EnVision Nexus system empowers researchers to efficiently screen millions of samples with unprecedented efficiency.

PerkinElmer Inc. Expands Life Sciences Portfolio With Acquisition Of Covaris Inc.

In December 2023, PerkinElmer Inc., a US-based MedTech company, acquired Covaris Inc. for an undisclosed amount. With this acquisition, Covaris' growth potential is anticipated to be accelerated, while PerkinElmer's existing life sciences portfolio is poised to expand into the rapidly growing diagnostics end market. Covaris Inc. is a US-based provider of high-throughput screening solutions. North America was the largest region in the high throughput screening market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the high throughput screening (HTS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the high throughput screening (HTS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The high-throughput screening (HTS) market consists of revenues earned by entities by providing services such as compound library screening, assay design and adaptation, and pilot screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The high-throughput screening (HTS) market also includes sales of lab equipment and supplies, chemicals, assay development tools, and data processing software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The high throughput screening (HTS) research report is one of a series of new reports from The Business Research Company that provides high throughput screening (HTS) market statistics, including the high throughput screening (HTS) industry's global market size, regional shares, competitors with an High throughput screening (HTS) market share, detailed high throughput screening (HTS) market segments, market trends and opportunities, and any further data you may need to thrive in the high throughput screening (HTS) industry. This high throughput screening (HTS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Artificial Intelligence (AI) In Biopharmaceuticals Market Definition And Segments

Artificial intelligence (AI) in biopharmaceuticals refers to applying various AI techniques to analyze complex biological data and improve various aspects of drug discovery, development, and delivery within the pharmaceutical industry. AI in biopharmaceuticals holds great promise for revolutionizing drug discovery, development, and delivery processes by accelerating timelines, reducing costs, and improving the efficiency and effectiveness of treatments. The main types of offerings in artificial intelligence (AI) in biopharmaceuticals are hardware, software, and services. Hardware refers to the physical components of a computer system, including devices such as memory, disk drives, controllers, and specialized software like database management systems. It includes various deployments, including cloud and on-premises, and the technologies used are machine learning, natural language processing, and deep learning, as well as applications used in business processes and supply chains, drug discovery, medical imaging and diagnostics, and precision medicine, end users are manufacturers, contract research organizations, and academic and government research institutes. The artificial intelligence (AI) in biopharmaceuticals market covered in this report is segmented – 1) By Offering: Hardware, Software, Services 2) By Deployment: Cloud, On-Premises 3) By Technology: Machine Learning, Natural Language Processing, Deep Learning, Other Technologies 4) By Application: Business Process And Supply Chain, Drug Discovery, Medical Imaging And Diagnostics, Precision Medicine 5) By End-Users: Manufacturers, Contract Research Organizations, Academic And Government Research Institutes The artificial intelligence (AI) in biopharmaceuticals market size has grown exponentially in recent years. It will grow from $1.19 billion in 2023 to $1.59 billion in 2024 at a compound annual growth rate (CAGR) of 33.8%. The growth in the historic period can be attributed to advancements in computational power, biomedical data explosion, precision medicine paradigm, regulatory support and guidance. The artificial intelligence (AI) in biopharmaceuticals market size is expected to see exponential growth in the next few years. It will grow to $4.99 billion in 2028 at a compound annual growth rate (CAGR) of 33.1%. The growth in the forecast period can be attributed to advancements in computational biology, integration of multi-modal data, convergence of ai and life sciences, regulatory support and frameworks, ethical and fair ai principles. Major trends in the forecast period include integration of multi-omics data, AI-driven drug design and discovery, explainable AI and regulatory acceptance, technological advancements, regulatory developments, and emerging opportunities.

Chronic Disease Prevalence Fueling Growth Of AI In Biopharmaceuticals Market

The growing prevalence of chronic diseases is expected to propel the growth of artificial intelligence (AI) in biopharmaceuticals market going forward. Chronic diseases are long-lasting conditions that generally progress slowly and may persist for years or even a lifetime. It arises from lifestyle factors, an aging population, genetic predispositions, and environmental factors. AI in biopharmaceuticals is increasingly used to manage chronic diseases because it analyzes large volumes of diverse data sources, identifies patterns, and personalizes treatment approaches. For instance, according to the National Library of Medicine, a US-based medical library, chronic diseases are expected to grow by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Therefore, the growing prevalence of chronic diseases drives the growth of artificial intelligence (AI) in the biopharmaceuticals market. Major companies operating in the artificial intelligence (AI) in biopharmaceuticals market are Apple Inc., Google LLC, Microsoft Corporation, Tencent Holdings Limited, Amazon Web Services Inc., International Business Machines Corporation, Exscientia Limited, NVIDIA Corporation, Amgen Inc., DeepMind Technologies Limited, Schrödinger Inc., XtalPi Inc., ConcertAI Inc., Insilico Medicine Inc., Recursion Pharmaceuticals, BenevolentAI, BioXcel Therapeutics, Atomwise Inc., BioAge Labs Inc., GNS Healthcare, Berg Health, Deep 6 AI Inc., Cloud Pharmaceuticals Inc., Numerate Inc., AI Therapeutics, Envisagenics, twoXAR Inc., Cyclica Inc.

Advancements In AI-Powered Solutions For Drug Discovery And Precision Medicine

Major companies operating in artificial intelligence (AI) in biopharmaceuticals focus on developing innovative advancements such as target and lead identification suite AI-powered solutions to accelerate drug discovery and precision medicine to transform life sciences organizations. These solutions for drug discovery and precision medicine encompass a variety of innovative approaches to developing new drugs and tailoring treatments to individual patients. For instance, in May 2023, Google LLC, a US-based provider of cloud computing services, launched two new AI-powered tools called target and lead identification suites, designed to help researchers predict and understand the structure of proteins, which is a fundamental part of drug development. Additionally, this suite will help researchers ingest, store, analyze, and share mass amounts of genomic data, which is crucial for precision medicine. Also, these tools aim to streamline the drug discovery process, reduce costs, and bring new treatments to market faster. By providing efficient data management, accurate predictions of protein structures, and advanced genomic analysis capabilities, these tools aim to revolutionize drug development processes and improve patient outcomes.

ZS Associates' Acquisition Of Trials.ai Inc. To Revolutionize Clinical Trial Design with AI

In February 2023, ZS Associates, a US-based management consulting and technology firm, acquired Trials.ai Inc. for an undisclosed amount. With this acquisition, Associates aims to enhance design processes within the pharmaceutical industry by leveraging artificial intelligence (AI) to optimize speed, improve participant experiences, and expedite the delivery of pharmaceutical therapies to the market. Trials.ai Inc. is a US-based company that focuses on revolutionizing clinical trials through artificial intelligence (AI) and machine learning (ML) technologies. North America was the largest region in the artificial intelligence (AI) in biopharmaceuticals market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) in biopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) in biopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The artificial intelligence (AI) in biopharmaceuticals market consists of revenues earned by entities by services such as drug discovery, personalized medicine analytics, clinical trial optimization, healthcare decision support, and data integration and analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) in biopharmaceuticals market also includes of sales of decision support System, predictive modeling tools, robotics, and automation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The artificial intelligence (AI) in biopharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI) in biopharmaceuticals market statistics, including artificial intelligence (AI) in biopharmaceuticals industry global market size, regional shares, competitors with an artificial intelligence (AI) in biopharmaceuticals market share, detailed artificial intelligence (AI) in biopharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in biopharmaceuticals industry. This artificial intelligence (AI) in biopharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.